top of page

Free Biopharma Daily Stock Updates - 07/07/21

$XBI $131.35 -1.7%

 

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

 

COVID Updates



Pipeline Updates

$ABUS +-0.0% Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent source


$SEEL -8.3% Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson’s Disease Pathology source


$TRVN +-0.0% Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects source


$NGM +1.1% NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors source


$GOSS -0.0% gossamer bio announces gb004 clinical trial data presentations at 2021 virtual congress of the european crohn’s and colitis organisation source


$ABEO -2.7% Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting source


$JAZZ +0.50% Health Canada Approves Vyxeos®, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML) source


$XENE +0.30% Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders source


$MRNA -5.0% Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine source


$CTXR +3.2% Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones source


$ATOS -2.5% Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia source


$INRLF +1.3% Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate source


$EVAX -3.3% Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8 source




Financial Updates

$BHVN +13.6% Biohaven Announces Preliminary 2q2021 Net Product Revenue For Nurtec Odt, The First And Only Migraine Medication For Both Acute And Preventive Treatment source


$ADAG +6.2% Adagene Announces Authorization of Share Repurchase Program up to US$20 Million source


$AKTX -4.1% Akari Therapeutics Announces Private Placement source


$BSGM -7.1% BioSig Announces Closing of Public Offering of Common Stock source


 

Posted by JM

0 comments

Comentários


bottom of page